Cargando…

Evolution of phage display libraries for therapeutic antibody discovery

Monoclonal antibodies (mAbs) and their derivatives have emerged as one of the most important classes of biotherapeutics in recent decades. The success of mAb is due to their high versatility, high target specificity, excellent clinical safety profile, and efficacy. Antibody discovery, the most upstr...

Descripción completa

Detalles Bibliográficos
Autor principal: Zhang, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210849/
https://www.ncbi.nlm.nih.gov/pubmed/37222232
http://dx.doi.org/10.1080/19420862.2023.2213793
_version_ 1785047155713507328
author Zhang, Yang
author_facet Zhang, Yang
author_sort Zhang, Yang
collection PubMed
description Monoclonal antibodies (mAbs) and their derivatives have emerged as one of the most important classes of biotherapeutics in recent decades. The success of mAb is due to their high versatility, high target specificity, excellent clinical safety profile, and efficacy. Antibody discovery, the most upstream stage of the antibody development pipeline, plays a pivotal role in determination of the clinical outcome of an mAb product. Phage display technology, originally developed for peptide directed evolution, has been extensively applied to discovery of fully human antibodies due to its unprecedented advantages. The value of phage display technology has been proven by a number of approved mAbs, including several top-selling mAb drugs, derived from the technology. Since antibody phage display was first established over 30 years ago, phage display platforms have been developed to generate mAbs targeting difficult-to-target antigens and tackle the drawbacks present in in vivo antibody discovery approaches. More recently, the new generation of phage display libraries have been optimized for discovery of mAbs with ”drug-like” properties. This review will summarize the principles of antibody phage display and design of three generations of antibody phage display libraries.
format Online
Article
Text
id pubmed-10210849
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-102108492023-05-26 Evolution of phage display libraries for therapeutic antibody discovery Zhang, Yang MAbs Review Monoclonal antibodies (mAbs) and their derivatives have emerged as one of the most important classes of biotherapeutics in recent decades. The success of mAb is due to their high versatility, high target specificity, excellent clinical safety profile, and efficacy. Antibody discovery, the most upstream stage of the antibody development pipeline, plays a pivotal role in determination of the clinical outcome of an mAb product. Phage display technology, originally developed for peptide directed evolution, has been extensively applied to discovery of fully human antibodies due to its unprecedented advantages. The value of phage display technology has been proven by a number of approved mAbs, including several top-selling mAb drugs, derived from the technology. Since antibody phage display was first established over 30 years ago, phage display platforms have been developed to generate mAbs targeting difficult-to-target antigens and tackle the drawbacks present in in vivo antibody discovery approaches. More recently, the new generation of phage display libraries have been optimized for discovery of mAbs with ”drug-like” properties. This review will summarize the principles of antibody phage display and design of three generations of antibody phage display libraries. Taylor & Francis 2023-05-24 /pmc/articles/PMC10210849/ /pubmed/37222232 http://dx.doi.org/10.1080/19420862.2023.2213793 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Review
Zhang, Yang
Evolution of phage display libraries for therapeutic antibody discovery
title Evolution of phage display libraries for therapeutic antibody discovery
title_full Evolution of phage display libraries for therapeutic antibody discovery
title_fullStr Evolution of phage display libraries for therapeutic antibody discovery
title_full_unstemmed Evolution of phage display libraries for therapeutic antibody discovery
title_short Evolution of phage display libraries for therapeutic antibody discovery
title_sort evolution of phage display libraries for therapeutic antibody discovery
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210849/
https://www.ncbi.nlm.nih.gov/pubmed/37222232
http://dx.doi.org/10.1080/19420862.2023.2213793
work_keys_str_mv AT zhangyang evolutionofphagedisplaylibrariesfortherapeuticantibodydiscovery